|
1
|
Holdhoff M and Grossman SA: Controversies
in the adjuvant therapy of high-grade gliomas. Oncologist.
16:351–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vehlow A and Cordes N: Invasion as target
for therapy of glioblastoma multiforme. Biochim Biophys Acta.
1836:236–244. 2013.PubMed/NCBI
|
|
3
|
Montana V and Sontheimer H: Bradykinin
promotes the chemotactic invasion of primary brain tumors. J
Neurosci. 31:4858–4867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Hegi ME, Gilbert MR and
Chakravarti A: Chemoradiotherapy in malignant glioma: Standard of
care and future directions. J Clin Oncol. 25:4127–4136. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu L, Lin DC, Yin D and Koeffler HP: An
emerging role of PARK2 in cancer. J Mol Med (Berl). 92:31–42. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poulogiannis G, McIntyre RE, Dimitriadi M,
Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams
DJ and Arends MJ: PARK2 deletions occur frequently in sporadic
colorectal cancer and accelerate adenoma development in Apc mutant
mice. Proc Natl Acad Sci USA. 107:pp. 15145–15150. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujiwara M, Marusawa H, Wang HQ, Iwai A,
Ikeuchi K, Imai Y, Kataoka A, Nukina N, Takahashi R and Chiba T:
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Oncogene. 27:6002–6011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tay SP, Yeo CW, Chai C, Chua PJ, Tan HM,
Ang AX, Yip DL, Sung JX, Tan PH, Bay BH, et al: Parkin enhances the
expression of cyclin-dependent kinase 6 and negatively regulates
the proliferation of breast cancer cells. J Biol Chem.
285:29231–29238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Picchio MC, Martin ES, Cesari R, Calin GA,
Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR,
et al: Alterations of the tumor suppressor gene Parkin in non-small
cell lung cancer. Clin Cancer Res. 10:2720–2724. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Veeriah S, Taylor BS, Meng S, Fang F,
Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W,
et al: Somatic mutations of the Parkinson's disease-associated gene
PARK2 in glioblastoma and other human malignancies. Nat Genet.
42:77–82. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pardo A, Gibson K, Cisneros J, Richards
TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M and
Kaminski N: Up-regulation and profibrotic role of osteopontin in
human idiopathic pulmonary fibrosis. PLoS Med. 2:e2512005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Zhang W, Li Y, Alvarez A, Li Z,
Wang Y, Song L, Lv D, Nakano I, Hu B, et al: SHP-2-upregulated ZEB1
is important for PDGFRα-driven glioma epithelial-mesenchymal
transition and invasion in mice and humans. Oncogene. 35:5641–5652.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT,
Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma
initiation, invasion and chemoresistance. EMBO Mol Med.
5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yeo CW, Ng FS, Chai C, Tan JM, Koh GR,
Chong YK, Koh LW, Foong CS, Sandanaraj E, Holbrook JD, et al:
Parkin pathway activation mitigates glioma cell proliferation and
predicts patient survival. Cancer Res. 72:2543–2553. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun X, Liu M, Hao J, Li D, Luo Y, Wang X,
Yang Y, Li F, Shui W, Chen Q and Zhou J: Parkin deficiency
contributes to pancreatic tumorigenesis by inducing spindle
multipolarity and misorientation. Cell Cycle. 12:1133–1141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu KJ and Yang MH: Epithelial-mesenchymal
transition and cancer stemness: The Twist1-Bmi1 connection. Biosci
Rep. 31:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo Z, Hardin H and Lloyd RV: Cancer
stem-like cells and thyroid cancer. Endocr Relat Cancer.
21:T285–T300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao D, Dai C and Peng S: Mechanism of the
mesenchymal-epithelial transition and its relationship with
metastatic tumor formation. Mol Cancer Res. 9:1608–1620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Gise A and Pu WT: Endocardial and
epicardial epithelial to mesenchymal transitions in heart
development and disease. Circ Res. 110:1628–1645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamada S, Okumura N, Wei L, Fuchs BC,
Fujii T, Sugimoto H, Nomoto S, Takeda S, Tanabe KK and Kodera Y:
Epithelial to mesenchymal transition is associated with shorter
disease-free survival in hepatocellular carcinoma. Ann Surg Oncol.
21:3882–3890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH,
Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y,
Pertsemlidis A and Kurie JM: Contextual extracellular cues promote
tumor cell EMT and metastasis by regulating miR-200 family
expression. Genes Dev. 23:2140–2151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chu K, Boley KM, Moraes R, Barsky SH and
Robertson FM: The paradox of E-cadherin: Role in response to
hypoxia in the tumor microenvironment and regulation of energy
metabolism. Oncotarget. 4:446–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
